Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 17 (SCARNA17) is a member of the small nucleolar RNAs (snoRNAs), specifically associated with the Cajal bodies in the nucleus. These RNAs act as guide RNAs for the chemical modification (such as pseudouridylation or methylation) of other RNA molecules, particularly spliceosomal and ribosomal RNAs, thus playing a role in the biogenesis and function of these ribonucleoprotein complexes. LOC124905173 encodes the RNA sequence for SCARNA17, but it is not a protein-coding gene, nor is it a typical receptor, enzyme, transporter, or classical pharmaceutical target. Its biological role is limited to RNA processing, and there are no known direct implications in disease, drug interactions, or use as a biomarker.\n\nIn summary: ENSG00000252143 / LOC124905173 encodes a small Cajal body-specific RNA, not a protein or conventional drug target. There is no evidence it functions as a receptor, enzyme, or other classic therapeutic target, nor is it implicated in disease, drug action, or safety concerns. If you need information on a typical druggable gene/protein, this locus is not suitable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small Cajal body-specific RNA 17.